Introduction {#S1}
============

Suffering comes in many ways for cancer patients, and pain is one of the most burdensome and prevalent symptoms they report. Over 30% of cancer patients describe their pain as distressing or even intolerable ([@B4]). Cancer treatment such as surgery, radiotherapy, and chemotherapy cause significant acute and chronic pain ([@B32]). It has been reported that nearly half of cancer patients experience pain, and about 40% of cancer survivors develop chronic pain ([@B32]). A western meta-analysis in 2016 reported that pain prevalence rates were 55% during cancer treatment, 39.3% post treatment, and 66.4% in metastatic or terminal disease ([@B45]). In mainland China, 49.8--80% of cancer patients report some degree of pain, and 11--30% of them reported high level of pain ([@B48]; [@B9]; [@B28]; [@B43]).

Pain has severe negative influence on cancer patient's quality of life (QoL). Patients often report that pain prevents them from focusing or thinking, and that it makes difficulty in performing normal daily activities ([@B4]). Studies also found significant relationship between persistent pain experience and emotional connectedness difficulties, and this relationship was mediated by psychological distress ([@B19]). Thus, researchers highlighted the importance of providing adequate pain treatment which may help to result in clinically improvements in health-related QoL ([@B37]).

Pain is influenced by several physiological, psychological, and behavioral factors ([@B36]). Studies found that patients with higher levels of psychological distress tended to report greater self-perceived pain as well as decreased self-perceived function ([@B3]; [@B7]), and anxiety, depression, and insomnia symptoms were consistently found to be correlated with the severity of pain ([@B15]; [@B49]; [@B12]). Additionally, a recent review concluded that depression was a possible predictor in the transition from acute to chronic pain in non-cancer patients ([@B23]). Besides depression, this review also suggested that "fear-avoidance" beliefs in the form of cognitive expectances was another significant predictor in chronicity ([@B23]). However, these factors have not been thoroughly investigated in cancer populations. As one of the most prevalent emotional burdens for cancer patients, fear of cancer progression (FoP) has received increasing attention in recent years. Significant negative associations were found between FoP and medicine adherence, QoL and patient's psychosocial well-being ([@B13]), and higher FoP was consistently found to be related to more physical symptoms ([@B25]). However, to the author's best knowledge, no study has previously investigated the association of FoP and cancer pain.

As suggested by the biopsychosocial models, an increasing number of researchers have delineated psychosocial variables to be important correlates of pain intensity ([@B47]). However, data on pain prevalence and its influencing factors in Chinese cancer populations are limited, and those studies were all published in Chinese and the majority of them only included small sample size and used single-item question to assess pain. [@B28] found that gender, education background, cancer stage, as well as type of painkiller significantly influenced patient's pain levels, while Chen's study indicated that lower family income, higher levels of anxiety and depression were associated with severer pain ([@B9]). A new study in 2018 suggested that patient's age, self-efficacy, and coping strategy significantly predicted a cancer patient's self-perceived pain ([@B10]).

In the current study, we aim to (1) estimate the prevalence of pain in Chinese cancer population using validated measurements; (2) test whether demographic, clinical as well as psychological factors are correlated with cancer pain; and (3) assess the relevance between pain and FoP. We hypothesize that: (1) compared to demographic and clinical variables, psychological factors play greater role in patient's self-perceived pain; (2) anxiety, depression, and insomnia symptoms are positively associated with cancer pain; and (3) patients who report higher FoP are more likely to report greater pain.

Materials and Methods {#S2}
=====================

Study Design and Setting {#S2.SS1}
------------------------

This is a cross-sectional study that involved three main hospitals in southern China. A power analysis was performed before recruitment to determine study sample size. All participants were recruited from the department of oncology (Nanfang Hospital), department of breast surgery (Guangzhou Women and Children's Medical Center), and department of radiotherapy (Guangdong Provincial People's Hospital) from January to October 2018. To be included in the study, participants needed to: (1) be above 18 years old; (2) had a clear diagnosis of cancer; (3) be able to read and write Mandarin or Cantonese. Participants were excluded if they had disturbance of consciousness, blind, or deaf.

Measures {#S2.SS2}
--------

### Demographic and Clinical Data {#S2.SS2.SSS1}

Patient's basic demographic (i.e., age, gender etc.) and clinical (i.e., cancer site, cancer stage etc.) data were collected by a specific question sheet. Information about patient's treatment received (chemotherapy and radiotherapy), smoking behavior, and physical comorbidity were assessed by "Yes/No" questions. Patient's personality tendency was measured by a single question derived from the Chinese version Personality Traits Questionnaire ([@B51]): what do you think is your dominant personality trait (Positive or Negative)? For patients who were uncertain about their disease stage, information was collected from the individual's medical notes.

### The McGill Pain Questionnaire-Short Form (MPQ-SF) {#S2.SS2.SSS2}

The MPQ-SF ([@B31]) is one of the most widely used tests for the measurement of pain and has been validated into Chinese language in 2013. The Chinese version of MPQ-SF has 17 items in total which consists of three subscales: pain rating index (PRI, item 1--15), visual analog scale (VAS, item 16), and present pain intensity (PPI, item 17). Item 1--11 represent the sensory dimension (PRI-sensory) of pain experience and item 12--15 represent the affective dimension (PRI-affective). These 15 PRI descriptors are rated on a Likert-type scale as 0 = none, 1 = mild, 2 = moderate, and 3 = severe, while the score of VAS (item 16) ranges from 0 (no pain) to 100 (worst possible pain), and the PPI (item 17) score ranges from 0 (no pain) to 5 (excruciating) ([@B35]).

### Athens Insomnia Scale (AIS) {#S2.SS2.SSS3}

The AIS ([@B39]) is commonly utilized in clinical practice as an instrument to assess the intensity of sleep-related problems, and it is also used as a screener in reliably establishing the diagnosis of insomnia. The AIS includes eight items. The first five are related to nocturnal sleep and the last three items are related to daytime dysfunction. All of the items are scored on a Likert-type scale ranging from 0 (no problem/none) to 3 (serious problem), and an individual's sleep outcome is finally evaluated by the sum score of all items. The Cronbach's alpha of AIS is 0.89 which shows satisfactory internal consistency. A cut-off of ≥6 on the AIS is used to assist the diagnosis of insomnia ([@B40]).

### Fear of Progression Questionnaire-Short Form (FoP-Q-SF) {#S2.SS2.SSS4}

The FoP-Q-SF is a 12-item scale used to assess cancer patient's fear of progression. It is the short form of the original 43-item Fear of Progression Questionnaire (FoP-Q) ([@B20]). All of the items are rated on a 5-point Likert scale, ranging from 1 (never) to 5 (very often). The resulting cumulative score of the FoP-Q-SF ranges from 12 to 60, and a score of 34 or above indicates a dysfunctional level of FoP ([@B21]). The psychometric properties of the Chinese FoP-Q-SF is satisfactory (Cronbach's alpha = 0.883) ([@B50]).

### Patient Health Questionnaire (PHQ-9) {#S2.SS2.SSS5}

The PHQ is a 9-item self-assessed measure that evaluates the degree of an individual's depressive symptoms. The item of PHQ ranges from 0 (not at all) to 3 (almost everyday) ([@B26]) and it has been validated in several specific clinical populations. The Chinese version of the scale showed excellent psychometric properties (internal consistency = 0.89) ([@B8]). A total score of ≥5 on the PHQ-9 indicated depressive symptoms.

### General Anxiety Disorder Scale (GAD-7) {#S2.SS2.SSS6}

The GAD is a 7-item scale used to measure a person's anxiety level. Response options are not at all, several days, more than half the days, and nearly every day, rated as 0, 1, 2, and 3, respectively ([@B42]). The original internal consistency of the scale was good (Cronbach's alpha = 0.92), and the Chinese version's Cronbach's alpha was 0.91 ([@B53]). A sum score of 5 or more indicated anxiety symptoms.

### The Holmes-Rahe Life Stress Inventory {#S2.SS2.SSS7}

The Life Stress Inventory was developed to test the relationship between illness and stress ([@B22]). It is also commonly known as the Social Readjustment Rating Scale (SRRS) and has been validated in Chinese ([@B52]). Forty-three major life stressors (such as death of a spouse/child, divorce, and retirement, etc.) were listed to test an individual's stress level. The more of the stressors one individual experienced, the higher risk of illness.

Data Collection {#S2.SS3}
---------------

Patients were consecutively recruited from three hospitals. All patients were approached in the waiting room before their appointment with their oncologist and were asked for participation. For those who showed interest in participating, a written informed consent form was provided, then they were asked to complete the information sheet and all scales. Participants were ensured that their personal information would be kept confidential and they could withdraw their participation at any time. The hospital Research Ethics Committee examined and approved the study (Ref No: NFEC-2018-038).

Data Analysis {#S2.SS4}
-------------

Statistical analyses were preformed using SPSS version 22.0 and the cutoff for statistical significance was set at 0.05 (2 sided). Descriptive statistics were used to calculate frequencies, means, and standard deviations. Difference in means were investigated using a *t* test for independent samples. Analysis of variance and *post hoc* test were used to identify group effects. Continuous variables that were not normally distributed were analyzed using Mann-Whitney U tests or Kruskal-Wallis tests (K-W tests), as appropriate. The associations between continuous variables were assessed using Pearson's correlation analysis if the variables were normally distributed, otherwise, Spearman's correlation was utilized. Hierarchical regression analyses were subsequently conducted to ascertain the associated factors of cancer pain (three subscales: PRI, VAS, and PPI). Three blocks were orderly included in each regression analyses. Demographic factors were entered in the first block, followed by the clinical/treatment factors, and the final block involved the psychological variables.

Results {#S3}
=======

Patient Characteristics {#S3.SS1}
-----------------------

A total of 887 patients were invited to participate the study and 566 (63.81%) of them agreed. Thirteen patients were then excluded from the study because they were teenagers (age under 18 years). Finally, 553 patients completed the survey. The mean age of patients is 47.23 (SD = 11.26, ranged from 23 to 90). The majority of the participants were female (91.7%), married (87.5%), diagnosed with breast cancer (84.6%), non-current smoker (96.2%) and had received chemotherapy (90.6%), and radiotherapy (86.6%). All participants were currently receiving active treatment (radiation/chemotherapy/drugs). Less than half of the participants experienced clinical insomnia (40.7%), FoP (29.8%), depressive or anxiety symptoms (42.0 and 30.7%, respectively). Of the 553 participants, 142 (25.68%) patients reported no pain (total score = 0), and the remaining 411 (74.32%) patients reported some degree of pain. Patient's demographic, clinical as well as psychological characteristics are presented in [Table 1](#T1){ref-type="table"}.

###### 

Demographic, clinical, and psychological characteristics of participants (*N* = 553).

                                                       **PRI-Total**   **VAS**        **PPI**                                      
  --------------------------------------- ------------ --------------- -------------- --------------- -------------- ------------- --------------
  **Sociodemographic**                                                                                                             
  **Gender**                                                                                                                       
  Male                                    46 (8.3)     5.67 ± 7.65                    24.78 ± 17.73                  1.57 ± 0.69   
  Female                                  507 (91.7)   5.10 ± 5.92     --0.508        25.21 ± 17.36   --0.235        1.64 ± 0.76   --0.618
  **Age**                                                                                                                          
  Age below 35                            71 (12.8)    4.83 ± 4.48                    25.77 ± 16.96                  1.59 ± 0.73   
  Age between 35-60                       391 (70.7)   4.82 ± 6.09                    23.73 ± 16.51                  1.62 ± 0.77   
  Age above 60                            91 (16.5)    6.80 ± 6.82     8.201^∗^       30.88 ± 20.09   11.807^∗∗^     1.71 ± 0.69   0.700
  **Marital Status**                                                                                                               
  Single                                  32 (5.8)     5.78 ± 4.80                    27.50 ± 19.84                  1.75 ± 0.76   
  Married                                 484 (87.5)   5.12 ± 6.14                    25.21 ± 17.52                  1.61 ± 0.73   
  Divorced                                16 (2.9)     4.75 ± 7.71                    23.13 ± 13.52                  1.81 ± 1.17   
  Widowed                                 21 (3.8)     5.19 ± 5.09     2.884          22.38 ± 12.21   0.219          1.86 ± 0.96   1.361
  **Monthly Salary (Yuan)**                                                                                                        
  Less than 3000                          262 (47.4)   6.15 ± 7.24                    26.22 ± 18.44                  1.68 ± 0.81   
  3000-5000                               147 (26.6)   4.89 ± 5.15                    27.21 ± 18.09                  1.65 ± 0.67   
  5000-10000                              93 (16.8)    4.10 ± 4.19                    22.58 ± 14.06                  1.67 ± 0.80   
  More than 10000                         51 (9.2)     2.69 ± 3.17     11.280^∗^      18.63 ± 12.81   11.405^∗∗^     1.29 ± 0.50   3.835^∗^
  **Clinical/Treatment**                                                                                                           
  **Cancer Site**                                                                                                                  
  Breast                                  468 (84.6)   5.17 ± 5.96                    25.34 ± 17.43                  1.65 ± 0.76   
  Nasopharynx                             30 (5.4)     4.97 ± 5.51                    24.00 ± 18.31                  1.67 ± 0.80   
  Colorectal                              36 (6.5)     4.39 ± 6.48                    23.89 ± 18.09                  1.47 ± 0.65   
  Leukemia                                19 (3.4)     6.32 ± 8.78     2.985          25.26 ± 13.89   1.191          1.53 ± 0.70   0.729
  **Stage**                                                                                                                        
  Stage 1                                 92 (16.6)    5.57 ± 5.99                    29.24 ± 20.23                  1.71 ± 0.66   
  Stage 2                                 219 (39.6)   4.37 ± 5.39                    24.25 ± 15.64                  1.61 ± 0.76   
  Stage 3                                 215 (38.9)   5.80 ± 6.90                    24.74 ± 17.95                  1.61 ± 0.79   
  Stage 4                                 27 (4.9)     4.85 ± 3.72     3.913          22.22 ± 13.96   4.281          1.67 ± 0.78   0.409
  **Daily Exercise Time**                                                                                                          
  None                                    69 (12.5)    6.54 ± 7.15                    25.94 ± 16.74                  1.74 ± 0.93   
  Less than 60 min                        427 (77.2)   5.12 ± 6.01                    25.20 ± 17.01                  1.63 ± 0.73   
  60 min and above                        57 (10.3)    3.68 ± 4.70     5.514          24.04 ± 20.76   3.135          1.53 ± 0.71   1.261
  **Current smoking**                                                                                                              
  Yes                                     21 (3.8)     3.38 ± 4.73                    25.24 ± 17.50                  1.52 ± 0.60   
  No                                      532 (96.2)   5.22 ± 6.11     --1.602        25.17 ± 17.38   --0.090        1.64 ± 0.76   0.664
  **Chemotherapy^a^**                                                                                                              
  Yes                                     501 (90.6)   5.29 ± 6.10                    25.49 ± 17.52                  1.65 ± 0.76   
  No                                      48 (8.7)     3.96 ± 5.86     --1.703        23.13 ± 16.00   --0.701        1.48 ± 0.65   1.485
  **Radiotherapy^a^**                                                                                                              
  Yes                                     479 (86.6)   4.99 ± 5.90                    25.28 ± 17.64                  1.64 ± 0.76   
  No                                      70 (12.7)    6.43 ± 7.19     --1.521        25.30 ± 15.67   --0.482        1.60 ± 0.75   0.401
  **Physical Comorbidity^a^**                                                                                                      
  Yes                                     364 (65.8)   4.70 ± 5.34                    24.23 ± 16.54                  1.62 ± 0.76   
  No                                      185 (33.5)   6.11 ± 7.27     --1.673        27.35 ± 18.82   --1.755        1.67 ± 0.74   0.804
  **BMI**                                                                                                                          
  Less than 18.5                          69 (12.5)    6.13 ± 7.85                    22.75 ± 16.53                  1.72 ± 0.80   
  18.5-25                                 385 (69.6)   5.05 ± 5.86                    25.58 ± 17.82                  1.59 ± 0.73   
  More than 25                            99 (17.9)    4.87 ± 5.44     0.337          25.25 ± 16.18   1.876          1.71 ± 0.82   1.478
  **AIS (Insomnia)**                                                                                                               
  Yes                                     225 (40.7)   7.33 ± 6.89                    30.00 ± 19.30                  1.85 ± 0.86   
  No                                      328 (59.3)   3.65 ± 4.92     --7.682^∗∗∗^   21.86 ± 15.08   --5.219^∗∗∗^   1.47 ± 0.63   --5.905^∗∗∗^
  **Psychological**                                                                                                                
  **Personality^a^**                                                                                                               
  Positive                                420 (75.9)   4.77 ± 5.70                    25.10 ± 16.76                  1.59 ± 0.68   
  Negative                                129 (23.3)   6.50 ± 7.08     −2.472^∗^      25.89 ± 19.35   --0.20         1.78 ± 0.95   −2.162^∗^
  **Number of stressful life event(s)**                                                                                            
  None                                    136 (24.6)   3.45 ± 4.77                    22.87 ± 16.10                  1.45 ± 0.61   
  Less than 3                             212 (38.3)   4.59 ± 5.00                    24.58 ± 16.21                  1.59 ± 0.70   
  3--5                                    132 (23.9)   6.36 ± 6.27                    26.89 ± 18.91                  1.80 ± 0.83   
  More than 5                             73 (13.2)    7.77 ± 8.91     23.397^∗∗∗^    28.08 ± 19.55   4.024          1.77 ± 0.92   6.050^∗∗∗^
  **Fear of Progression**                                                                                                          
  Yes                                     165 (29.8)   8.20 ± 7.58                    29.94 ± 20.17                  1.87 ± 0.88   
  No                                      388 (70.2)   3.85 ± 4.76     --7.331^∗∗∗^   23.14 ± 15.63   --3.527^∗∗∗^   1.53 ± 0.67   --5.013^∗∗∗^
  **Depressive symptom**                                                                                                           
  Yes                                     232 (42.0)   7.56 ± 7.27                    28.36 ± 18.44                  1.84 ± 0.88   
  No                                      321 (58.0)   3.41 ± 4.28     --7.706^∗∗∗^   22.87 ± 16.20   --3.832^∗∗∗^   1.48 ± 0.61   --5.275^∗∗∗^
  **Anxiety symptom**                                                                                                              
  Yes                                     170 (30.7)   7.73 ± 7.47                    29.41 ± 19.05                  1.84 ± 0.85   
  No                                      383 (69.3)   4.01 ± 4.94     --6.150^∗∗∗^   23.29 ± 16.25   --3.748^∗∗∗^   1.54 ± 0.69   --4.303^∗∗∗^

a

Four participants did not provide relevant data (

n

= 549);

b

Mann-Whitney U test;

c

Kruskal-Wallis test. PRI, pain rating index; VAS, visual analog scale; PPI, present pain intensity;

∗

P

\< 0.05;

∗∗

P

\< 0.01;

∗∗∗

P

\< 0.001.

Univariate Analysis {#S3.SS2}
-------------------

On univariate analysis, low monthly income, insomnia, FoP, depressive, and anxiety symptoms were significantly associated with greater cancer pain (PRI-total, VAS, and PPI subscales). Patients who were older were more likely to report higher scores on PRI-total and VAS. Compared to pessimists, optimists reported lower ratings on PRI-total and PPI. Additionally, we found patients who were experiencing more stressful life events were more likely to report higher levels of pain on PRI-total and PPI (see [Table 1](#T1){ref-type="table"}).

Correlations Between Continuous Variables {#S3.SS3}
-----------------------------------------

[Table 2](#T2){ref-type="table"} presents the bivariate correlation matrix of continuous study variables. Score of FoP, anxiety, insomnia, and depressive symptoms were significantly associated with different subscales of pain score. The only non-significant correlation in the matrix was between insomnia symptoms and VAS (*r* = 0.052).

###### 

Bivariate correlation matrix of continuous study variables.

                            **1**       **2**       **3**       **4**       **5**       **6**       **7**       **8**       **9**
  ------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -------
  1\. Fear of Progression   --                                                                                              
  2\. Depressive symptoms   0.508^∗∗^   --                                                                                  
  3\. Anxiety symptoms      0.480^∗∗^   0.838^∗∗^   --                                                                      
  4\. Insomnia symptoms     0.101^∗^    0.161^∗∗^   0.143^∗∗^   --                                                          
  5\. PRI-Sensory           0.289^∗∗^   0.338^∗∗^   0.252^∗∗^   0.123^∗∗^   --                                              
  6\. PRI-Affective         0.375^∗∗^   0.485^∗∗^   0.423^∗∗^   0.207^∗∗^   0.655^∗∗^   --                                  
  7\. PRI-Total             0.343^∗∗^   0.417^∗∗^   0.333^∗∗^   0.162^∗∗^   0.965^∗∗^   0.829^∗∗^   --                      
  8\. VAS                   0.218^∗∗^   0.229^∗∗^   0.191^∗∗^   0.052       0.320^∗∗^   0.335^∗∗^   0.352^∗∗^   --          
  9\. PPI                   0.232^∗∗^   0.319^∗∗^   0.250^∗∗^   0.131^∗∗^   0.463^∗∗^   0.450^∗∗^   0.497^∗∗^   0.375^∗∗^   --

∗

P

\< 0.05;

∗∗

P

\< 0.01; PRI, pain rating index; VAS, visual analog scale; PPI, present pain intensity.

Hierarchical Regression Model {#S3.SS4}
-----------------------------

The corresponding factors that shown significant correlation with cancer pain in previous univariate analyses were then introduced in each regression model (PRI-total, VAS, and PPI model) accordingly as independent variables. Demographic, clinical, and psychological factors were orderly entered in blocks as model 1, 2, and 3. The Durbin-Watson (DW) value of each model, which was a number that tested for autocorrelation in the residuals, was all satisfactory (ranged from 1.820 to 2.184). The variance inflation factor (VIF) ([@B46]), which quantified the severity of multicolinearity, was all less than 10 (ranged from 1.00 to 3.86).

[Tables 3a](#T3a){ref-type="table"}--[c](#T3c){ref-type="table"} present the results of hierarchical multiple regression of the variables associated with PRI-Total, VAS, and PPI. Among all the tested variables, depressive symptom appeared to have the strongest association with PRI-Total (β = 0.333, *P* \< 0.001), VAS (β = 0.159, *P* = 0.043) and PPI (β = 0.301, *P* \< 0.001), which demonstrated that those who were depressed were at higher risk of experiencing greater pain. FoP was the second strongest factor associated with PRI-Total (β = 0.231, *P* \< 0.001) and VAS (β = 0.142, *P* = 0.004), however, it was not significantly associated with PPI. Insomnia symptom was positively associated with PRI-Total (β = 0.096, *P* = 0.012) and PPI (β = 0.080, *P* = 0.0497), however, it did not significantly correlate with VAS. Age, and anxiety symptom, were not statistically significant in all regression analyses. In all, for each regression model, psychological variables showed stronger association with patient's pain experience than demographic as well as clinical factors.

###### 

Hierarchical multiple regression of the factors associated with PRI-Total (*n* = 553).

  **Factors**                  **Model 1**   **Model 2**   **Model 3**                                                                                                             
  ---------------------------- ------------- ------------- ------------- --------- --------- --------- ------- --------- --------- --------- --------- ------- --------- --------- ---------
  Age                          0.018         0.023         0.034         0.808     0.419     0.023     0.023   0.042     1.002     0.317     0.042     0.021   0.077     1.966     0.050
  Monthly salary               --1.083       0.257         --0.178       --4.217   \<0.001   --1.005   0.255   --0.165   --3.942   \<0.001   --0.399   0.253   --0.066   --1.576   0.116
  Insomnia symptoms                                                                          0.074     0.020   0.151     3.633     \<0.001   0.047     0.019   0.096     2.521     0.012
  Fear of Progression                                                                                                                        0.144     0.033   0.231     4.420     \<0.001
  Anxiety symptoms                                                                                                                           --0.110   0.105   --0.073   --1.049   0.295
  Depressive symptoms                                                                                                                        0.432     0.094   0.333     4.595     \<0.001
  Personality                                                                                                                                --1.032   0.504   --0.094   --2.050   0.041
  Number of Stressful events                                                                                                                 0.456     0.275   0.073     1.660     0.097
  R^2^                                                                             0.034                                           0.057                                           0.232
  Adjusted R ^2^                                                                   0.031                                           0.052                                           0.220
  R^2^ Change                                                                      0.034                                           0.023                                           0.175
  F Change                                                                         9.800                                           13.200                                          24.731
  *P*                                                                              \<0.001                                         \<0.001                                         \<0.001

PRI, pain rating index; the Durbin-Watson value of the model was 2.184. The variance inflation factor (VIF) ranged from 1.01 to 3.72.

###### 

Hierarchical multiple regression of the factors associated with VAS (*n* = 553).

  **Factors**           **Model 1**   **Model 2**   **Model 3**                                                                                                       
  --------------------- ------------- ------------- ------------- --------- ------- --------- ------- ------- --------- ------- --------- ------- --------- --------- ---------
  Age                   0.054         0.066         0.035         0.814     0.416   0.057     0.066   0.037   0.868     0.386   0.078     0.065   0.050     1.197     0.232
  Monthly salary        --2.072       0.741         --0.119       --2.795   0.005   --2.006   0.744   0.115   --2.697   0.007   --1.249   0.736   --0.072   --1.697   0.090
  Insomnia symptoms                                                                 0.063     0.060   0.045   1.059     0.290   0.017     0.059   0.012     0.289     0.773
  Fear of Progression                                                                                                           0.253     0.087   0.142     2.916     0.004
  Anxiety symptoms                                                                                                              --0.093   0.329   --0.022   --0.283   0.777
  Depressive symptoms                                                                                                           0.589     0.291   0.159     2.026     0.043
  R^2^                                                                      0.016                                       0.018                                         0.075
  Adjusted R^2^                                                             0.013                                       0.013                                         0.065
  R^2^ Change                                                               0.016                                       0.002                                         0.057
  F Change                                                                  4.598                                       1.121                                         11.162
  *P*                                                                       0.010                                       0.290                                         \<0.001

VAS, visual analog scale; the Durbin-Watson value of the model was 1.820. The variance inflation factor (VIF) ranged from 1.02 to 3.62.

###### 

Hierarchical multiple regression of the factors associated with PPI (*n* = 553).

  **Factors**                  **Model 1**   **Model 2**   **Model 3**                                                                                                         
  ---------------------------- ------------- ------------- ------------- --------- ------- --------- ------- --------- --------- ------- --------- ------- --------- --------- ---------
  Monthly salary               --0.078       0.032         --0.103       --2.421   0.016   --0.070   0.032   --0.093   --2.201   0.028   --0.017   0.033   --0.022   --0.503   0.615
  Insomnia symptoms                                                                        0.008     0.003   0.124     2.926     0.004   0.005     0.002   0.080     1.967     0.0497
  Fear of Progression                                                                                                                    0.008     0.004   0.097     1.760     0.079
  Anxiety symptoms                                                                                                                       --0.014   0.014   --0.073   --0.975   0.330
  Depressive symptoms                                                                                                                    0.049     0.012   0.301     3.903     \<0.001
  Personality                                                                                                                            --0.019   0.067   --0.014   --0.289   0.773
  Number of Stressful events                                                                                                             0.039     0.036   0.050     1.085     0.279
  R^2^                                                                             0.011                                         0.026                                         0.120
  Adjusted R^2^                                                                    0.009                                         0.022                                         0.109
  R^2^ Change                                                                      0.011                                         0.015                                         0.094
  F Change                                                                         5.860                                         8.559                                         11.658
  *P*                                                                              0.016                                         0.004                                         \<0.001

PPI, present pain intensity; the Durbin-Watson value of the model was 1.958. The variance inflation factor (VIF) ranged from 1.00 to 3.67.

Discussion {#S4}
==========

The current study is one of the few epidemiological studies that examined the factors associated with cancer patient's pain experience in mainland China, and it is the first study to investigate the association of FoP and self-perceived pain. In the past, pain was seen only as a biomedical issue. However, nowadays, people have widely recognized the fact that psychological, social as well as environmental factors significantly influence a patient's pain experience ([@B17]). Studies revealed that pain experienced over the disease course or during the final cancer stages is not linear or predictable, and an individual's tolerance levels of pain could be impeded by emotional distress ([@B14]). This highlighted the importance of psychological factors in coping with cancer pain.

In present, pain is considered as the fifth vital sign of a cancer patient's well-being along with signs of respiration, blood pressure, temperature, and heart rate ([@B5]). Our study found that 74.32% of cancer patients in Southern China experience some degree of pain. This figure seemed higher than the rates reported by western researchers which indicated that pain prevalence averaged 50--55% across the continuum from diagnosis through survivorship/end of life ([@B44]; [@B45]). One possible reason is that various pain measures were utilized in different study samples, which impedes the direct comparison of results.

Evidence is irrefutable that psychosocial factors play a great role in the relationship between objective pathophysiology and patient's subjective experience of pain ([@B47]). As hypothesized, and consistent with existing studies, our study found that anxiety ([@B33]), and depressive symptoms negatively impact a patient's self-assessed pain ([@B11]). Previous studies have reported a high prevalence of depression in patients with chronic pain, and the figure is significantly higher than in the general population and in those without chronic pain ([@B15]; [@B12]). Additionally, strong evidence has been provided that depression, anxiety, and FoP were associated with the severity of physical symptoms ([@B34]; [@B9], [@B10]; [@B25]). The related symptoms of loss of motivation, hopelessness, pessimism, fatigue, and disturbed sleep might be potential reasons to explain patient's increased pain. Additionally, like kinesiophobia, a significant factor which hinders patient's rehabilitation and prolongs disability as well as pain ([@B16]), FoP plays a similar role in cancer patient's recovery and might contribute to the increase and/or maintenance of pain perception.

When coping cancer or other life-threatening diseases, personality is one of the most clearly documented variables ([@B1]) and has been widely considered as an significant independent variable ([@B29]). However, in our study, personality was only significantly associated with PRI-total score. One potential reason is that in the current study, personality characteristics was assessed using single-item question, which was insufficient to examine the association in detail. In univariate analysis, patients with more stressful life events were more likely to experience cancer pain. However, the association was no longer significant in further regression analyses. Previous studies assumed that managing stressful life events could largely waste patient's mental energy and resources ([@B30]), therefore, makes them more vulnerable, both psychologically and physically.

Inconsistent with previous findings ([@B9], [@B10]; [@B28]), this study found no relationship between age, gender, cancer stage and patient's pain experience. Several studies reported that younger patients were more likely to report greater pain as well as pain-related distress ([@B2]; [@B6]; [@B27]), however, we found contrary results in our univariate analysis. The reason why we found contradictory results might due to the difference in study sample and participant's cultural background. Pain issue is multifaceted and complex. Further prospective longitudinal studies are warranted to examine their effects in detail.

Limitations {#S4.SS1}
-----------

There are a number of limitations of the current study. First of all, this study was based on a cross-sectional cohort, the causal relationships between tested variables and cancer pain are still unclear. Longitudinal cohort studies are necessary to identify causal associations. Second, patient's insomnia, anxiety as well as depressive symptoms were measured only by self-rated questionnaires. No psychiatrist was involved to confirm clinical diagnosis. Also, single item question was used to measure patient's personality tendency and no psychometric information was provided. Assessment bias may exist and can hardly be eliminated from cross-sectional studies. Further studies using more extensive and objective measurement tools would be beneficial. Third, only hospitals in southern China were included and the majority of the participants were female patients diagnosed with breast cancer. A potential sample bias may exist, and the research findings cannot be generalized to the entire Chinese cancer population. A national study with various cancer populations would be beneficial. Last but not least, more information about the clinical/treatment characteristics of the sample should be included, such as time since diagnosis and surgery type, as those factors may also impact patient's pain experience.

Implication {#S4.SS2}
-----------

Multidisciplinary groups are necessary in oncology settings to integrate care for pain management. It has been proved by previous meta-analysis and high-quality RCT studies that psychological and behavioral interventions could clinically improve patient's cancer-related pain ([@B38]; [@B24]). Hypnosis and coping skill training that includes cognitive behavioral therapy components and relaxation with imagery have the strongest evidence in improving pain severity for patients across disease stage ([@B41]; [@B18]). However, these specific pain treatments are inadequate in mainland China. In most of the cases, patients could not be ensured effective pain management ([@B28]). Thus, alongside the pharmacological management of pain, psychological pain management should be made more available in health care in China.

Conclusion {#S5}
==========

This study demonstrated that insomnia, depressive symptom, and fear of progression in cancer patients generally links to greater self-assessed pain. On the basis of the findings, it is important to evaluate each individual in detail with respect to psychological distress and pain severity when planning treatment and rehabilitation. Multidisciplinary helping groups and relevant coping skill training should be provided to improve patient's pain management as well as their quality of life.
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